UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

 

FORM 15

 

Certification and Notice of Termination of Registration

Under Section 12( g ) of the Securities Exchange Act of 1934

or Suspension of Duty to File Reports Under Sections 13 and

15( d ) of the Securities Exchange Act of 1934

 

Commission File Number 000-51312

 

  SHENGTAI PHARMACEUTICAL, INC.

 

(Exact name of registrant as specified in its charter)

 

Changda Road East

Development District, Changle County

Shandong, PRC

 

(Address, including zip code, and telephone number, including area code,

of registrant’s principal executive offices)

 

Common Stock par value $0.001  

(Title of each class of securities covered by this Form)

 

None

 

(Titles of all other classes of securities for which a duty to file reports under

Section 13(a) or 15(d) remains)

 

Please place an X in the box(es) to designate the appropriate rule provision(s) relied upon to terminate or suspend the duty to file reports:

 

Rule 12g-4(a)(1) x
Rule 12g-4(a)(2) ¨
Rule 12h-3(b)(1)(i) x
Rule 12h-3(b)(1)(ii) ¨
Rule 15d-6 ¨

 

Approximate number of holders of record as of the certification or notice date:   45 

 

Pursuant to the requirements of the Securities Exchange Act of 1934, Shengtai Pharmaceutical, Inc. has caused this certification/notice to be signed on its behalf by the undersigned duly authorized person.

 

Date: August 30, 2013 SHENGTAI PHARMACEUTICAL, INC.
   
    By:   /s/ Qingtai Liu
    Name: Qingtai Liu
    Title: Chief Executive Officer

 

 

 

Shengtai Pharmaceutical (GM) (USOTC:SGTI)
Gráfico Histórico do Ativo
De Jan 2025 até Fev 2025 Click aqui para mais gráficos Shengtai Pharmaceutical (GM).
Shengtai Pharmaceutical (GM) (USOTC:SGTI)
Gráfico Histórico do Ativo
De Fev 2024 até Fev 2025 Click aqui para mais gráficos Shengtai Pharmaceutical (GM).